Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study

Daniele Pastori, Roberto Carnevale, Roberto Cangemi, Mirella Saliola, Cristina Nocella, Simona Bartimoccia, Tommasa Vicario, Alessio Farcomeni, Francesco Violi, Pasquale Pignatelli, Daniele Pastori, Roberto Carnevale, Roberto Cangemi, Mirella Saliola, Cristina Nocella, Simona Bartimoccia, Tommasa Vicario, Alessio Farcomeni, Francesco Violi, Pasquale Pignatelli

Abstract

Background: Hemorrhagic risk assessment is a crucial issue in patients with nonvalvular atrial fibrillation (NVAF) who are receiving oral anticoagulant therapy (OAT). Our aim was to analyze the relationship between vitamin E, which possesses anticoagulant properties, and bleeding events in NVAF patients.

Methods and results: In this retrospective observational study we analyzed baseline serum cholesterol-adjusted vitamin E (vit E/chol) levels in 566 consecutive patients (59% males, mean age 73.6 years) receiving OAT followed up for a mean time of 22 months. Mean time in therapeutic INR range (TTR) was 64%. The overall incidence rate of any bleeding event was 9.2/100 person-years. Compared to patients who did not bleed, those who experienced bleeding events (n=92, 73 minor and 15 major bleedings and 4 cerebral hemorrhages according to International Society on Thrombosis and Haemostasis [ISTH] ) classification) showed a significant difference for history of coronary heart disease (P=0.039), HAS-BLED score (P=0.002), and vit E/chol levels (P<0.001). Higher vit E/chol serum levels were found in patients who bled compared to those who did not (5.27 ± 1.93 versus 4.48 ± 1.97 μmol/cholesterol; P<0.001), with a progressive increase from minor (5.16 ± 1.91 μmol/mmol cholesterol, P=0.006) to major bleedings (5.72 ± 2.0 μmol/mmol cholesterol, P=0.008). A Cox proportional hazard model demonstrated that serum vit E/chol quartiles (global P=0.0189) and HAS-BLED scores (P=0.005) predicted bleeding events.

Conclusions: In a NVAF population being treated with warfarin, serum vitamin E predicted hemorrhagic events. Further study is necessary to see if the relationship between serum levels of vitamin E and bleeding is still maintained with the use of new anticoagulants.

Trial registration: ClinicalTrials.gov NCT01882114.

Keywords: anticoagulation; atrial fibrillation; bleeding; tocopherol.

Figures

Figure 1.
Figure 1.
Kaplan–Meier estimates of time to main outcome events by vitamin E quartiles.
Figure 2.
Figure 2.
Kaplan–Meier estimates of time to secondary outcome events during the follow‐up according to median baseline value of vitamin E.

References

    1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22:983-988
    1. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof PEuropean Heart Rhythm Association Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011; 106:997-1011
    1. Yung D, Kapral MK, Asllani E, Fang J, Lee DSInvestigators of the Registry of the Canadian Stroke Network Reinitiation of anticoagulation after warfarin‐associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol. 2012; 28:33-39
    1. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26:1471-1477
    1. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004; 164:880-884
    1. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151:713-719
    1. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349:1019-1026
    1. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception‐cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996; 348:423-428
    1. Cangemi R, Pignatelli P, Carnevale R, Corazza GR, Pastori D, Farcomeni A, Basili S, Davì G, Ferro D, Hiatt WR, Licata G, Lip GY, Loffredo L, Mannucci PM, Vestri A, Violi FCollaboration with the ARA PACIS Study Group Cholesterol‐adjusted vitamin E serum levels are associated with cardiovascular events in patients with non‐valvular atrial fibrillation. Int J Cardiol. 2013. 10.1016/j.ijcard.2013.04.142.
    1. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347:781-786
    1. de Gaetano GCollaborative Group of the Primary Prevention Project Low‐dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 2001; 357:89-95
    1. Cook NR, Albert CM, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med. 2007; 167:1610-1618
    1. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999; 354:447-455
    1. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294:56-65
    1. Leppälä JM, Virtamo J, Fogelholm R, Huttunen JK, Albanes D, Taylor PR, Heinonen OP. Controlled trial of alpha‐tocopherol and betacarotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol. 2000; 20:230-235
    1. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2008; 300:2123-2133
    1. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342:154-160
    1. Miller ER, Pastor‐Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta‐analysis: high‐dosage vitamin E supplementation may increase all‐cause mortality. Ann Intern Med. 2005; 142:37-46
    1. Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, Hamada K, Blumberg JB. Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status. Am J Clin Nutr. 2004; 80:143-148
    1. Traber MG. Vitamin E and K interactions—a 50‐year‐old problem. Nutr Rev. 2008; 66:624-629
    1. Dowd P, Zheng ZB. On the mechanism of the anticlotting action of vitamin E quinone. Proc Natl Acad Sci USA. 1995; 92:8171-8175
    1. Furie B, Bouchard BA, Furie BC. Vitamin K‐dependent biosynthesis of gamma‐carboxyglutamic acid. Blood. 1999; 93:1798-1808
    1. Ferro D, Basili S, Praticò D, Iuliano L, FitzGerald GA, Violi F. Vitamin E reduces monocyte tissue factor expression in cirrhotic patients. Blood. 1999; 93:2945-2950
    1. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Vitamin E inhibits collagen‐induced platelet activation by blunting hydrogen peroxide. Arterioscler Thromb Vasc Biol. 1999; 19:2542-2547
    1. Stanger MJ, Thompson LA, Young AJ, Lieberman HR. Anticoagulant activity of select dietary supplements. Nutr Rev. 2012; 70:107-117
    1. Williams B. The year in hypertension. J Am Coll Cardiol. 2006; 48:1698-1711
    1. D'Agostino RB, Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117:743-753
    1. Grundy SM, Brewer HB, Jr, Cleeman JI, Smith SC, Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109:433-438
    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15:539-553
    1. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:1977-2016
    1. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285:2864-2870
    1. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user‐friendly score (HAS‐BLED) to assess 1‐year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138:1093-1100
    1. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69:236-239
    1. Martínez‐González MA, Fernández‐Jarne E, Serrano‐Martínez M, Wright M, Gomez‐Gracia E. Development of a short dietary intake questionnaire for the quantitative estimation of adherence to a cardioprotective Mediterranean diet. Eur J Clin Nutr. 2004; 58:1550-1552
    1. Schulman S, Kearon CSubcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. J Thromb Haemost. 2005; 3:692-694
    1. Thygesen K, Alpert JS, White HDJoint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole‐Wilson PA, Gurfinkel EP, Lopez‐Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernández‐Avilés F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio‐Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck‐Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez‐Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al‐Attar N. Universal definition of myocardial infarction. Circulation. 2007; 116:2634-2653
    1. Bieri JG, Tolliver TJ, Catignani GL. Simultaneous determination of alpha‐tocopherol and retinol in plasma or red cells by high pressure liquid chromatography. Am J Clin Nutr. 1979; 32:2143-2149
    1. Traber MG, Jialal I. Measurement of lipid‐soluble vitamins—further adjustment needed? Lancet. 2000; 355:2013-2014
    1. Marsh SA, Coombes JS. Vitamin E and a‐lipoic acid supplementation increase bleeding tendency via an intrinsic coagulation pathway. Clin Appl Thromb Hemost. 2006; 12:169-173
    1. Freedman JE, Farhat JH, Loscalzo J, Keaney JF., Jr α‐Tocopherol inhibits aggregation of human platelets by a protein kinase C‐dependent mechanism. Circulation. 1996; 94:2434-2440
    1. Celestini A, Pulcinelli FM, Pignatelli P, Lenti L, Frati G, Gazzaniga PP, Violi F. Vitamin E potentiates the antiplatelet activity of aspirin in collagen‐stimulated platelets. Haematologica. 2002; 87:420-426
    1. Schürks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta‐analysis of randomised controlled trials. BMJ. 2010; 341:c5702.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever